AML Treatment in Untreated Adult Patients

• Status: Unknown status
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The present therapy intends to be an homogeneous treatment for AML patients based on a pretreatment with hydroxiurea plus an induction therapy with the standard arm with Daunorubicine as according to EORTC-GIMEMA AML10 study.

The post-remissional treatment is based on transplant with HLA compatible donor is foreseen for all patients and autologous transplant for those without HLA compatible donor available.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
• Treatments: Daunorubicin

Criteria

Inclusion Criteria:

• AML "de novo" with bone marrow blasts <=30%

• Performance status: 0-3

• FAB subtype: all except M3

• Written informed consent

Exclusion Criteria:

• age <15 years and >= 61 years

• pretreated AML with chemiotherapy (except Idrossiurea) or radiotherapy or corticosteroids for more than 7 days.

• diagnosis of acute promyelocitic leukemia (M3)

• Performance status = 4

• Uncontrolled infection